ChemoCentryx, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.